Compare SURG & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | BCDA |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | 20 | 21 |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 12.9M |
| IPO Year | N/A | N/A |
| Metric | SURG | BCDA |
|---|---|---|
| Price | $0.62 | $1.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 600.0K | 53.5K |
| Earning Date | 04-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $136.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $1.00 |
| 52 Week High | $3.45 | $3.10 |
| Indicator | SURG | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 34.80 |
| Support Level | $0.46 | $1.00 |
| Resistance Level | $0.94 | $1.30 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 36.38 | 0.00 |
Surgepays Inc is a wireless and point of sale technology company focused on serving underserved and value-conscious consumers through a combination of retail distribution and digital acquisition channels. It provides mobile connectivity, financial technology services, and transaction processing solutions through an integrated platform that combines wireless services with point of sale software and retail distribution. It enables in-store and online activation of wireless services, prepaid top-ups, and financial transactions, allowing consumers to access essential services in both local and digital environments. Its segments are wireless services or MVNO Telecommunications, platform services or MVNE Enablement Platform (HERO), and wholesale enablement or Comprehensive Platform Services.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).